Morgan Stanley Boosts Henry Schein (NASDAQ:HSIC) Price Target to $58.00

Henry Schein (NASDAQ:HSIC) had its target price hoisted by research analysts at Morgan Stanley from $55.00 to $58.00 in a report released on Wednesday,Benzinga reports. The brokerage presently has an “underweight” rating on the stock. Morgan Stanley’s price target would indicate a potential downside of 19.67% from the company’s previous close.

Several other brokerages also recently commented on HSIC. Robert W. Baird reiterated a “neutral” rating and set a $72.00 target price (down from $82.00) on shares of Henry Schein in a research note on Monday, July 14th. Barrington Research set a $79.00 target price on Henry Schein in a research note on Wednesday. Wells Fargo & Company lifted their price target on Henry Schein from $70.00 to $76.00 and gave the stock an “equal weight” rating in a report on Wednesday. Leerink Partners set a $75.00 price target on Henry Schein in a report on Monday, July 14th. Finally, JPMorgan Chase & Co. dropped their price target on Henry Schein from $80.00 to $76.00 and set an “overweight” rating for the company in a report on Thursday, August 7th. Five equities research analysts have rated the stock with a Buy rating, eight have given a Hold rating and one has given a Sell rating to the company. According to MarketBeat, Henry Schein currently has an average rating of “Hold” and an average target price of $75.92.

Henry Schein Stock Up 0.8%

HSIC stock traded up $0.59 during mid-day trading on Wednesday, reaching $72.20. The company had a trading volume of 951,203 shares, compared to its average volume of 1,719,352. The company has a debt-to-equity ratio of 0.51, a current ratio of 1.41 and a quick ratio of 0.78. The stock has a 50 day simple moving average of $66.17 and a two-hundred day simple moving average of $68.61. The company has a market capitalization of $8.76 billion, a price-to-earnings ratio of 23.30, a PEG ratio of 2.06 and a beta of 0.81. Henry Schein has a 52 week low of $60.56 and a 52 week high of $82.49.

Henry Schein (NASDAQ:HSIC) last posted its quarterly earnings results on Tuesday, November 4th. The company reported $1.38 earnings per share for the quarter, beating analysts’ consensus estimates of $1.27 by $0.11. The firm had revenue of $3.34 billion during the quarter, compared to the consensus estimate of $3.28 billion. Henry Schein had a return on equity of 14.36% and a net margin of 3.05%. Henry Schein has set its FY 2025 guidance at 4.880-4.960 EPS. As a group, equities analysts predict that Henry Schein will post 4.74 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Henry Schein

Institutional investors and hedge funds have recently made changes to their positions in the stock. Teacher Retirement System of Texas bought a new stake in shares of Henry Schein during the 1st quarter valued at about $3,293,000. OneDigital Investment Advisors LLC boosted its position in shares of Henry Schein by 22.5% during the 1st quarter. OneDigital Investment Advisors LLC now owns 4,917 shares of the company’s stock valued at $337,000 after purchasing an additional 903 shares in the last quarter. IFM Investors Pty Ltd boosted its position in shares of Henry Schein by 6.6% during the 1st quarter. IFM Investors Pty Ltd now owns 23,831 shares of the company’s stock valued at $1,737,000 after purchasing an additional 1,482 shares in the last quarter. DekaBank Deutsche Girozentrale boosted its position in shares of Henry Schein by 0.8% during the 1st quarter. DekaBank Deutsche Girozentrale now owns 961,161 shares of the company’s stock valued at $65,205,000 after purchasing an additional 7,369 shares in the last quarter. Finally, Nisa Investment Advisors LLC boosted its holdings in Henry Schein by 5.8% in the first quarter. Nisa Investment Advisors LLC now owns 31,866 shares of the company’s stock worth $2,183,000 after acquiring an additional 1,751 shares in the last quarter. Institutional investors and hedge funds own 96.62% of the company’s stock.

About Henry Schein

Henry Schein, Inc provides health care products and services to dental practitioners, laboratories, physician practices, and ambulatory surgery centers, government, institutional health care clinics, and other alternate care clinics worldwide. It operates through two segments, Health Care Distribution, and Technology and Value-Added Services.